-
-
-
-
-
-
-
Daré Bioscience reports interim Phase 3 results for hormone-free contraceptive
-
-
-
-
-
-
-
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth
-
-
-
-
-
-
-
Dare Bioscience regains rights to contraceptive drug from Bayer
-
-
-
-
-
-
-
Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025
-
-
-
-
-
-
-
Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025
-
-
-
-
-
-
-
Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application P
-
-
-
-
-
-
-
Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available v
-
1,198,417 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

